

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
10 September 2021 (10.09.2021)



(10) International Publication Number
WO 2021/178253 A1

(51) International Patent Classification:

A61K 31/136 (2006.01) A61K 31/245 (2006.01)

A61K 31/165 (2006.01)

(21) International Application Number:

PCT/US2021/020145

(22) International Filing Date:

27 February 2021 (27.02.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/984,731 03 March 2020 (03.03.2020) US

(71) Applicants: SYSTIMMUNE, INC. [US/US]; 15318 NE 95th St, Redmond, Washington 98052 (US). SICHUAN BAILI PHARMACEUTICAL CO. LTD. [CN/CN]; 161 Baili Road, Wenjiang District, Chengdu, Sichuan (CN).

(72) Inventors: CHATTERJEE, Soumili; 19505 25th Dr SE, Bothell 98012 (IN). GOULET, Dennis R.; 6788 138th Ave NE #626, Redmond, Washington 98052 (US). WAIGHT, Andrew; 8442 NE169th Place, Kenmore, Washington 98028 (US). MAK, Nga Sze Amanda; 9752 Marine View Dr, Mukilteo, Washington 98275 (US). KHALILI, Jahan; 12635 NE 130th Way #A103, Kirkland, Washington 98034 (US). ZHU, Yi; 8-24, Building 6, No. 6, Lidu Road, Wuhou District, Chengdu, Sichuan (CN).

(74) Agent: HAN, Zhihua; EpiMED LLC, 10398 NE 17th St. Unit 306, Bellevue, Washington 98004 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available):

AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available):


ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: ANTI-CD19 ANTIBODIES AND METHODS OF USING AND MAKING THEREOF

Figure 1 shows an increase in humanness scores (Z-score) from mouse sequence (grey line) to the humanized framework (dark line) in the variable regions of humanized BU12, H4 (Vk for kappa light chain in 1A, and VH for heavy chain in 1B) and H5 (Vk for kappa light chain in 1C and VH for heavy chain in 1D).



(57) Abstract: An isolated monoclonal antibody (mAb) or antigen-binding fragment thereof having a binding specificity to human CD19, wherein the isolated mAb or antigen-binding fragment comprises an amino acid sequence having an identity with a sequence selected from SEQ ID NO. 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 91, or 93, wherein the identity is not less than at least 95%.

WO 2021/178253 A1